Aktis Oncology, Inc. (AKTS) vs MoonLake Immunotherapeutics (MLTX)
Aktis Oncology, Inc. and MoonLake Immunotherapeutics are both Biotechnology companies. Aktis Oncology, Inc. and MoonLake Immunotherapeutics are of similar size ($1.1B and $1.0B). MoonLake Immunotherapeutics has the higher net margin (0.00% vs −782.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Aktis Oncology, Inc. leads on 7 and MoonLake Immunotherapeutics on 6.
Valuation
Profitability
| Metric | AKTS | MLTX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 0.00% | 65.16% |
| Operating margin | (939.13%) | 0.00% | 0.00% |
| Net margin | (781.95%) | 0.00% | 0.00% |
| Free cash flow margin | (1,442.91%) | 0.00% | 0.00% |
| Return on equity | (34.45%) | (67.08%) | (57.72%) |
| Return on assets | (27.09%) | (51.00%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack